SCHEMBL1651127

SCHEMBL1651127

COc1cc(O)cc(/C=C(/O/C(=C/c2cc(O)cc(OC)c2)c2ccccc2C)c2ccccc2C)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 3/20 0.51
▸ KMT2A Q03164 3/20 0.51
▸ KDM4E B2RXH2 3/20 0.51
▸ MAPT P10636 2/20 0.51
▸ ALDH1A1 P00352 2/20 0.51
▸ CYP3A4 P08684 2/20 0.51
▸ HPGD P15428 2/20 0.51
▸ USP2 O75604 1/20 0.51
▸ TP53 P04637 1/20 0.51
▸ SMN1; SMN2 Q16637 1/20 0.51
▸ TRPV1 Q8NER1 1/20 0.51
▸ HSD17B10 Q99714 1/20 0.51
▸ PTGS2 P35354 4/20 0.45
▸ CYP1A1 P04798 4/20 0.45
▸ CYP1B1 Q16678 4/20 0.45
▸ TTR P02766 2/20 0.45
▸ ALOX5 P09917 2/20 0.45
▸ ABL1 P00519 3/20 0.41
▸ BCR P11274 3/20 0.41
▸ NQO2 P16083 3/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1650246 0.93 NQO2 (0.44) MEN1KMT2AKDM4EMAPTALDH1A1
SCHEMBL1650245 0.93 NQO2 (0.44) MEN1KMT2AKDM4EMAPTALDH1A1
SCHEMBL1650451 0.81 MEN1 (0.59) MEN1KMT2AKDM4EMAPTALDH1A1
SCHEMBL1652049 0.77 NQO2 (0.49) MEN1KMT2AKDM4EMAPTALDH1A1
SCHEMBL1654001 0.76 MEN1 (0.47) MEN1KMT2AKDM4EMAPTALDH1A1
SCHEMBL1650904 0.76 NQO2 (0.59) MEN1KMT2AKDM4EMAPTALDH1A1
SCHEMBL1650240 0.75 MEN1 (0.49) MEN1KMT2AKDM4EMAPTALDH1A1
SCHEMBL1650706 0.72 NQO2 (0.51) MEN1KMT2AKDM4EMAPTALDH1A1
SCHEMBL1650710 0.72 NQO2 (0.51) MEN1KMT2AKDM4EMAPTALDH1A1
SCHEMBL12729801 0.69 KDM4E (0.59) MEN1KMT2AKDM4EMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10112881-B2 Skin lightening compounds WISYS TECHNOLOGY FOUNDATION, INC. (US) 2018-10-30 — — US disclosed
US-20170197897-A1 Skin Lightening Compounds WISYS TECH FOUND INC (US) 2017-07-13 — — US disclosed
WO-2016014529-A1 SKIN LIGHTENING COMPOUNDS WISYS TECHNOLOGY FOUNDATION, INC. (US) 2016-01-28 — — WO disclosed
US-8530512-B2 Broad spectrum gram-positive antimicrobials and anthelmintics with efficacy against drug-resistant strains and Mycobacterium species MONTE AARON P (US) 2013-09-10 — — US disclosed
US-20110092578-A1 Broad Spectrum Gram-Positive Antimicrobials and Anthelmintics with Efficacy Against Drug-Resistant Strains and Mycobacterium Species MONTE AARON P 2011-04-21 — — US disclosed
US-20070292545-A1 ANTI-INFECTIVE AGENTS AND METHODS OF USE WISYS TECHNOLOGY FOUNDATION 2007-12-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10112881-B2 Skin lightening compounds TYR, MC1R, MCHR1 MEN1 1459/4885KMT2A 1981/4885KDM4E 1634/4885
US-20110092578-A1 Broad Spectrum Gram-Positive Antimicrobials and Anthelmintics with Efficacy Against Drug-Resistant Strains and Mycobacterium Species ABCC1, H1-3, H1-2 MEN1 3549/4885KMT2A 1759/4885KDM4E 1076/4885
US-20070292545-A1 ANTI-INFECTIVE AGENTS AND METHODS OF USE H1-3, H1-0, H1-2 MEN1 2664/4885KMT2A 1847/4885KDM4E 1612/4885
US-20170197897-A1 Skin Lightening Compounds TYR, MC1R, MCHR1 MEN1 1398/4885KMT2A 2209/4885KDM4E 2442/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback